Inoperable advanced liver cancer that returns or persists despite prior therapy is challenging to treat successfully. In this study, researchers are evaluating the safety and effectiveness of an investigational drug called GC33 in patients with previously treated advanced or metastatic hepatocellular carcinoma that cannot be surgically removed.
GC33 is an antibody that targets a protein called GPC3 and triggers an immune response against GPC3-expressing cancer cells, which may result in cancer cell death. GPC3 is produced at high levels in hepatocellular carcinoma. Patients in this study will be randomly assigned to receive GC33 or a placebo.